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Human immunodeficiency virus (HIV; known previously as HTLV-III/LAV)
is the etiologic agent for the acquired immunodeficiency syndrome (AIDS) and
a spectrum of related disorders (1, 2). The virus is tropic and cytopathic for T
lymphocytes that express the differentiation antigen CD4 (T4/Leu-3) on their
cell surface (1-4). Both the binding of virus to susceptible target cells and the
cell fusion that is a characteristic manifestation of HIV-induced cytopathology
involve specific interactions between the viral envelope glycoprotein and cell
surface CD4 (3-7).
The protein backbone ofthe HIV envelope glycoprotein has an M,. ^-88,000
(8). The molecule is heavily glycosylated and exists in several forms. It appears
to be synthesized as a 160,000 precursor, which is cleaved into gp120 and gp41
(transmembrane) portions (8). To investigate the possible role of the carbohy-
drate component of the viral glycoprotein in the processes of virion infectivity
and virally induced cell fusion, we tested the effects of a panel of lectins of
different binding specificities on in vitro assays of these processes. Our results
suggest that mannose-containing carbohydrate moieties on the viral envelope
glycoprotein are involved, either directly or indirectly, in envelope interactions
with cell surface CD4.
Materials and Methods
Cell Lines.
￿
The CD4+ T cell lines VB (6, 7) and H9 (2) have been described in detail
elsewhere. Cell lines were maintained in RPMI 1640 supplemented with 10% heat-
inactivated FCS and 2 mM 1-glutamine. Assays offree virus infectivityand virally induced
fusion (see below) were conducted in the same medium.
HIV Preparation. For use in assays of virion infectivity (see below) we used the
reference isolate ofLAV (1), maintained in chronically infected CEM-CCRF cells. Super-
natants from these chronically infected cultures were filtered through 0.22-jum filters
before use asa source ofinfectious virus.
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Reverse Transcriptase (RT) Assay.
￿
Magnesium-dependent RT activity, typical of HIV,
was measured as described previously (9).
Assay ofHIV-induced Cell Fusion.
￿
A cell-mixing syncytium-induction assay was used to
evaluate virally induced cell fusion . To 5 X 104 HIV (HTLV-IIIb)-infected H9 cells seeded
in the flat-bottom wells (^x0 .28 cm2) of 96-well microtiter plates, 5 X 104 uninfected VB
cells were added, to yield a final volume of 100 ,.l. Under these conditions, syncytia arise
over a period of 2-4 h through cell fusion involving interactions between the HIV
envelope glycoprotein and CD4 (6, 7). Mixed cells were cultured at 37 °C in humidified
5% C02, and observed at specific time points by light microscopy at X 200 for the
presence of multinucleated giant cells. Syncytia were evaluated according to a semiquan-
titative scoring system based on the following criteria: the absence of multinucleated giant
cells was scored as negative (-). Wells with rare but unequivocal multinucleated giant cells
(greater than four included nuclei within a common cell membrane) were scored as 1 .
Wells with more frequent giant cells, but in which the majority of X 200 fields did not
contain giant cells were scored as 2 . Wells with giant cells in most but not all X 200 fields
were scored as 3, and wells with syncytia in all X 200 fields were scored as 4. Cells were
treated with varying concentrations of lectins or competitive inhibitors of lectin binding,
and the effects on subsequent giant cell formation were evaluated. For some experiments
(see below), either the H9 cells or the VB cells were pretreated with lectin and then
washed extensively with lectin-free medium before mixing. In other experiments, the
lectins were present in the mixed cell culture for the duration of the experiment.
Lectins and Competitors.
￿
Con A, lentil lectin, and lectins from garden pea, sweet pea,
soy bean, fava bean, Bandieraea simplicifolia, and wheat germ were purchased from Sigma
Chemical Co. (St. Louis, MO). PHA was purchased from Burroughs-Wellcome, Ltd.,
Beckenham, United Kingdom. a-methyl-D-mannoside and tunicamycin were purchased
from Sigma Chemical Co. Con A from Pharmacia Fine Chemicals (Uppsala, Sweden) and
from E-Y Laboratories (Burlingame, CA) were also tested.
Assay of Free Virus Infectivity.
￿
For each experimental group, 4 X 106 VB cells were
incubated at 37°C for 1 h in 500 Al containing 105 cpm RT activity virus equivalent. To
evaluate the effects of Con A on free virus infectivity, the virus preparation was pretreated
with either Con A (50 pg/ml), Con A and a-methyl-D-mannoside (0.1 M), or medium for
30 min before addition to VB cells. A 1-h incubation was then performed with the treated
virus inoculum to allow adsorption, and the cells were resuspended to a density of 106
cells/ml with lectin or inhibitor added to the desired final concentration. Cells were then
cultured for 1 wk and observed daily for the presence of virus-induced cell fusion, with
samples of cell-free culture supernatants taken on days 4 and 7 for assay of RT activity.
Cells were resuspended to their original density, with fresh lectin and/or inhibitor added,
at the time of supernatant harvest.
Recombinant Vaccinia Virus.
￿
A recombinant vaccinia virus (VSC-25), which contains
the gene for the envelope glycoprotein of HIV, was generated as described elsewhere
(10). Infection of VB cells with VSC-25 results in the specific cell surface expression of
HIV envelope glycoprotein, leading to CD4-dependent cell fusion (7, 10). No other HIV-
determined proteins are expressed. Infection of VB cells with wild type vaccinia virus
does not induce cell fusion. To document cell surface expression of the HIV envelope
glycoprotein in these studies, we used indirect immunofluorescence analysis, using serum
from a patient with circulating HIV envelope-reactive antibody. The serum was exten-
sively absorbed on VB cells infected with wild type vaccinia virus before use in immuno-
fluorescence assays in order to remove nonspecific or vaccinia-specific reactivities. For
fusion assays and immunofluorescence analysis (7), VB cells were infected as described
(7), washed, then cultured for 7 h in the presence or absence of tunicamycin (20 t+g/ml).
Results
Lectins with specificity for D-mannose inhibited HIV-induced cell fusion (Table
1). In numerous experiments, lectins having other specificities had little or no
effect on virus-induced fusion, with the exception of PHA, which acceleratedLIFSON ET AL.
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TABLE I
Inhibition ofHIV-induced Cell Fusion by Mannose-specific Lectins
HIV-infected H9 cells were mixed with uninfected VB cells in the continuous presence oflectins at the indicated
concentrations.
* Lectins were purchased from: Sigma Chemical Co., St. Louis, MO; Pharmacia Fine Chemicals, Uppsala, Sweden;
E-Y Laboratories, San Mateo, CA; Wellcome, Ltd., Beckenham, United Kingdom. When more than one supplier
is designated for a single lectin, preparations from both were tested, with similar results. Lectin carbohydrate
specificities are as described by suppliers.
* Syncytia were scored at 4 h, as described in the text.
TABLE II
Con A Inhibits HIV-induced Cell Fusion by Binding to Infected Cells
For pretreatment studies, 106 cellsofthe indicated population were treated with Con A at 50 pg/ml in the presence
or absence of 0.1 M a-methyl-D-mannoside for 1 h at 37°C then washed before mixing with an equal number of
cells of the other population. Mixed cells were then cultured in the continued presence or absence of 0.1 M a-
methyl-D-mannoside, and syncytia were scored at 4 h.
the fusion process slightly. Con A inhibited syncytium formation in a dose-
dependent fashion, and the inhibition could be specifically competed with a-
methyl-D-mannoside (Table 11). Concentrations of Con A that inhibited cell
fusion did not decrease the viability ofcultured cells over the period ofthe assay,
as assessed by trypan blue exclusion (data not shown).
Pretreatment ofthe uninfected VB cells with 50 Aig/ml of Con A, followed by
extensive washing before mixing with infected H9 cells in the absence of
additional Con A, did not affect subsequent cell fusion. However, identical Con
A pretreatment of the infected H9 cells before mixing with untreated VB cells
completely blocked cell fusion (Table 11). The effect of Con A on cell fusion was
reversible, as infected H9 cells treated with 50 Ag/ml Con A for 1 h then washed
extensively underwent fusion if 0.1 M a-methyl-D-mannoside was added in the
absence ofadditional Con A (Table 11).
The possibility existed that ConAinhibited HIV-inducedcellfusion bybinding
Lectin source Supplier* Carbohydrate-
binding specificity
Contents-
tion ion in assay
ml)
Syncy-
tium
score
None None None 4
Con A (jack bean) Sigma, Pharmacia a-D-man 100 -
a-D-glc 10 -
1 4
Lens culinaris (lentil) Sigma, E-Y a-D-man 100 -
Pisum sativum (garden pea) Sigma, E-Y a-D-man 100 1
Lathyrus odoratus (sweet pea) Sigma a-D-man 100 2
Viciafaba (fava bean) Sigma D-man 100 3
Bandeiraea simplicifolia BS-1I Sigma a-D-gal 100 4
a-D-gaINAc
PHA (red kidney bean) Wellcome Unknown 20 4
Glycine max (soybean) Sigma o-gaINAc 100 4
Helix pomatia (snail) Sigma D-galNAc 100 4
Dolichos biflorus (horse gram) Sigma a-o-gaINAc 100 4
Triticum vulgaris (wheat germ) Pharmacia (D-glcNAc)2 100 4
NeuNAc
Population pretreated Pretreatment Competitor added Untreated popula-
tion added
Syncytium
score
None None None H9H,v, VB 4
VB Con A None H9Hw 4
H9,v Con A None VB -
VB and H9H,v Con A None None -
H9tnv Con A a-methyl-D-mannoside VB 42104 LIFSON ET AL.
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TABLE III
Con A Inhibits HIVEnvelope Glycoprotein-induced Cell Fusion in a
Recombinant Vaccinia Virus System
VB cells were either sham-infected with wild type vaccinia virus (VSC-STD) or VSC-25, a
recombinant vaccinia virus that contains the gene for the HIV envelope glycoprotein, as
described (7, 10). Cells were then cultured in the presence or absence of Con A (50,ug/ml)
with or without 0.1 M a-methyl-D-mannoside. For tunicamycin treatment, cells were placed
in 20 Ag/ml tunicamycin immediately after the virusadsorption incubation (7, 10), and were
cultured in the continued presence of the drug.
TABLE IV
Con A Inhibits HIV Virion Infectivityfor VB Target Cells
For each experimental group, 4 X 108 VB cells were incubated at 37°C for 1 h in 500 Al
containing 105 cpm RT activity virus equivalent. To evaluate the effects of Con A on free
virus infectivity, the virus preparation was pretreated with either Con A (50,ug/ml), Con A
and a-methyl-o-mannoside (0.1 M), or culture medium for 30 min at 37°C before addition
to VB cells. After a 1-h incubation with the treated virus inoculum to allow adsorption, the
cells were resuspended to a density of 108 cells/ml, with lectin or inhibitor added to the
desired final concentration. Cells were then cultured for 1 wk, observed daily for the
presence of virus-induced cell fusion, with samples ofcell-free culture supernatants taken on
days 4 and 7 for assay of RT activity. Cells were resuspended to their original density, with
fresh lectin and/or inhibitor added, at the time of supernatant harvest. The RT activity
detected on day 4 in the HIV inoculated, Con A-treated cells probably reflects residual
virus from the initial inoculation.
to mannose residues on cell surface viral envelope glycoprotein, preventing the
envelope/CD4 interactions required for cell fusion (6, 7). To evaluate this
possibility, we used a recombinant vaccinia virus containing the envelope gene
of HIV (7, 10). Infection of VB cells with the recombinant virus induced CD4-
dependent cell fusion, and this fusion was inhibited by Con A (Table III). The
Con A-mediated inhibition could be competed with a-methyl-D-mannoside (Ta-
ble III). Although tunicamycin treatment completely inhibited fusion of the
vaccinia recombinant-infected cells (Table III), this treatment also moderately
decreased cell surface expression of HIV envelope glycoprotein, as detected by
immunofluorescence analysis (data not shown) .
Con A pretreatment of an infectious virus preparation, with the continued
presence of lectin during subsequent culture, blocked the in vitro infectivity of
HIV virions, as assessed by the development ofcytopathology and RT activity in
supernatants ofthe infected cultures (Table IV). The Con A-mediatedinhibition
could be specifically competed by a-methyl-D-mannoside (Table IV).
HIV inoc-
ulation Con A
a-Methyl-
D-manno-
side Syncytia
Day 4
RT activity Syncytia
Day 7
RT activity
- - - - NT - 2,996
- + - - NT - 2,708
+ - - 4 391,490 4 181,620
+ + - - 15,475 - 3,160
+ + + 4 178,853 4 423,713
Infection Treatment Syncytium score
None None
VSC-STD None
VSC-25 None 4
VSC-25 Con A
VSC-25 Con A a-methyl-o-mannoside 4
VSC-25 TunicamycinLIFSON ET AL.
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Discussion
The envelope glycoprotein of HIV is heavily glycosylated, and some of the
glycosylation sites are conserved between different isolates of HIV, suggesting
that glycosylation may play an important role in the biological activity of the
virus (11). Our results, showing inhibition ofHIV infectivity and cell fusion by
lectins with specificity for D-mannose, are consistent with this hypothesis. Pre-
treatment studies suggested that Con A blocked fusion through an interaction
with viral envelope glycoprotein displayed on the surface ofinfected cells.
Additional studies using a recombinant vaccinia virus system, in which the
envelope glycoprotein ofHIV is expressed on the surface ofinfected cells in the
absence of synthesis of any other HIV proteins, indicate that Con A inhibition
ofHIV envelope glycoprotein-mediated cellfusion involves interactions between
Con A and the viral envelope glycoprotein. Tunicamycin, which prevents gly-
cosylation by inhibiting the formation of a key intermediate in lipid linked
oligosaccharide assembly (12), blocked HIV envelope-induced fusion in the
recombinant vaccinia virus system, providing additional evidence for the role of
the carbohydrate portion of the HIV envelope glycoprotein in inducing cell
fusion. However, interpretation of findings in the tunicamycin blocking studies
is complicated by the fact that the drug decreased the amount ofHIV envelope
displayed on the surface of recombinant vaccinia virus-infected cells.
Mannose-binding lectins thus appear to inhibit the processes of AIDS virus-
induced cell fusion and in vitro infectivity through interactions with the viral
envelope glycoprotein . The molecular basis for these effects is unknown. Con A
may bind to carbohydrate residues involved in envelope glycoprotein/CD4
interactions, may interfere with protein/protein interactions through steric
hindrance, or alternatively, may cause a conformational change in the structure
of the envelope molecule upon binding. Regardless of the precise mechanism,
these findings, implying an important role for HIV envelope glycoprotein car-
bohydrate in virion infectivityand virus-inducedcell fusion are relevant to efforts
to develop a protective vaccine against the AIDS virus, and suggest that an
optimal viral subunit vaccine should incorporate appropriately processed (gly-
cosylated) viral protein antigen.
Summary
Human immunodeficiency virus(HIV)envelope glycoprotein interactions with
cell surface CD4 are involved in both virion infectivity and virally mediated cell
fusion. D-mannose-specific lectins such as Con A specifically blocked virion
infectivity and cell fusion. Studies with a recombinant vaccinia virus containing
the HIV envelope gene demonstrated that Con A-mediated inhibition ofHIV-
induced fusion involved lectin binding to the viral envelope glycoprotein. These
results indicate the importance of envelope glycosylation in the pathobiology of
HIV infection, and suggest potential mechanisms for interfering with HIV
infectivity and cytopathology.
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